E3 Ligase
信号通路图
研究领域
抑制剂选择性比较
E3 Ligase 产品
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1029 |
Lenalidomide (CC-5013)Lenalidomide (CC-5013)是一种TNF-α分泌抑制剂，在PBMCs中IC50为13 nM。Lenalidomide (CC-5013) 是 ubiquitin E3 ligase cereblon (CRBN) 的配体，它通过CRBN-CRL4泛素连接酶引起两个淋巴样转录因子IKZF1和IKZF3的选择性泛素化和降解。Lenalidomide 可促进 cleaved caspase-3 的表达、抑制 VEGF 的表达并诱导凋亡。 |
Effect of lenalidomide treatment (50 mg/kg/day, p.o. for 3 days) on expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Fas, Fas ligand (FasL), and cleaved caspase-3 in myocardium from lean and ob/ob mice. (a) Representative gel blots of TNF-α, IL-6, Fas, FasL, cleaved caspase-3 and α-Tubulin (as loading control) using specific antibodies. (b) TNF-α. |
|
| S1567 |
PomalidomidePomalidomide (CC-4047)抑制LPS诱导的TNF-α释放，在PBMCs中IC50为13 nM。Pomalidomide 可以在PROTAC中用作靶向 E3 ligase 和抑制 E3 ligase protein cereblon (CRBN)。Pomalidomide可促进凋亡和细胞周期阻滞。 |
OPM2 cells stably expressing either NT or CRBN shRNA were seeded and incubated with pomalidomide at the indicated concentration, followed by MTT assay at day 3 after adding drugs. Each experimental condition was performed in triplicate and repeated at least once.
|
|
| S1193 |
Thalidomide沙利度胺作为一种镇静药，免疫调节剂，也用于研究治疗许多癌症的症状。沙利度胺抑制E3泛素连接酶（一种CRBN-DDB1-Cul4A复合物）。 |
(E) MM.1S cells were treated with Thal(Thalidomide) or Pom for 48 hours. In each case, western blot was carried out using cell lysates and the indicated Abs.
|
|
| S8449New |
VH298VH298 是一种有效的 VHL (Von Hippel-Lindau, the E3 ligase) 的抑制剂，可稳定 HIF-α。VH298 可阻断VHL:HIF-α的相互作用，在等温滴定热分析 (ITC) 中的Kd值为90 nM、在竞争性荧光偏振测定中的Kd值为80 nM。VH-298可用于PROTAC技术。 |
||
| S9605New |
ApcinApcin (APC inhibitor) 是一种有丝分裂的 anaphase-promoting complex/cyclosome (APC/C) 的E3连接酶活性的抑制剂，其可与Cdc20结合并竞争性地抑制含D-box底物的泛素化。 |
||
| S0095New |
VL285VL285 是一种有效的 VHL ligand 对应的IC50值为0.34 μM，可降解HaloTag7融合蛋白。HaloPROTAC3 衍生自 VL285。 |
||
| S0097New |
(S,R,S)-AHPC (MDK7526)(S,R,S)-AHPC (MDK7526) 是一种 VH032-based VHL ligand，可用于募集 von Hippel-Lindau (VHL)蛋白。(S,R,S)-AHPC 可能对 androgen receptor 的靶向降解有用。(S,R,S)-AHPC 可以通过接头与蛋白质的配体例如BCR-ABL1连接，以形成PROTAC例如GMB-475。GMB-475 可在 Ba/F3 细胞中诱导BCR-ABL1降解，IC50值为1.11 μM。 |
||
| S2225 |
TAMETAME是一种APC抑制剂。 |
Knockdown of p21 or inhibiting APC/C by TAME sensitized NSCLC cells to 5-FU. Cells were treated with 5-FU. 2 days after treatment, surviving cells were stained with cystal violet. Representive microscopic fields were shown. The blue stained cells were counted and shown in histogram at the right side.
|
|
| S2781 |
RITA (NSC 652287)RITA (NSC 652287)诱导DNA-蛋白质和DNA-DNA交联，检测不到DNA单链断裂，通过靶向作用于p53，也抑制MDM2-p53相互作用。 |
To determine the number of viable cells, cells were serum starved for 8 hours and treated with 25 nM RITA and stimulated with 1ug/mL SDF1α for 48 hours in serum-free media. After 48 hours, cells were harvested and counted by trypan blue exclusion, using standard methods.
|
|
| S2754 |
AT406 (SM-406)AT406 (SM-406, ARRY-334543, Debio1143) 是一种有效的，拟Smac的IAP(通过E3泛素连接酶起作用的凋亡蛋白抑制剂)拮抗剂，与XIAP-BIR3， cIAP1-BIR3和cIAP2-BIR3结合，Ki为66.4 nM， 1.9 nM和5.1 nM，比作用于Smac AVPI肽亲和力高50到100倍。Phase 1。 |
G, cells treated with the SM406 (1 μmol/L) for 48 hours were subjected to Western blotting. |
|
| S5315 |
PRT4165PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro. |
||
| S8760 |
Iberdomide(CC220)Iberdomide (CC-220) 是一种新型口服免疫调节化合物，靶向cereblon（cereblon是CRL4CRBN E3泛素连接酶复合体的一部分），IC50为60 nM。Iberdomide (CC-220) 可诱导凋亡并具有抗肿瘤和免疫刺激的活性。 |
||
| S7892 |
Avadomide(CC-122)CC-122，一种新型的多效性修饰剂化合物，在弥漫性大B细胞淋巴瘤（DLBCL）中具有抗肿瘤、免疫调节活性。其分子靶标为cereblon (CRBN)，CRBN是E3泛素化连接酶复合体CRL4CRBN的底物受体。 |
||
| S8652 |
Skp2 inhibitor C1 (SKPin C1)Skp2 inhibitor C1 (SKPin C1)是一种高选择性的Skp2-mediated p27 degradation小分子抑制剂。 |
||
| S2678 |
NSC 207895NSC 207895 (XI-006) 抑制MDMX，IC50为2.5 μM，促进p53稳定/激活和DNA损伤，也调节MDM2（E3连接酶）。 |
Median overall survival of mice (n = 5 mice in vehicle and PYR-41; n = 4 mice in NSC group) inoculated with IOWA-1T xenografts were increased to 43 ± 0.5 and 39 ± 2 days with PYR-41 (PYR) and NSC-207895 (NSC), respectively, compared with a vehicle-treated control group 33 ± 1 days (*p < 0.05).
|
|
| S1061 |
Nutlin-3Nutlin-3是一种有效的，选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂，无细胞试验中IC50为90 nM；可稳定p53缺陷细胞中的p73。 |
Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.
|
|
| S1172 |
JNJ-26854165 (Serdemetan)JNJ-26854165 (Serdemetan)是一种HDM2泛素连接酶拮抗剂，作用于p53野生型细胞，诱导早期凋亡，在缺乏功能性p53的细胞中，抑制细胞增殖而延迟细胞凋亡。 |
|
|
| S8975New |
CC-92480CC-92480 是一种新型蛋白降解剂，是一种 cereblon E3 ligase 调节剂(CELMoD)，并具有抗骨髓瘤活性。 |
||
| S8888New |
GMB-475GMB-475 是一种靶向蛋白水解的嵌合体(PROTAC)，它以变构方式靶向 BCR-ABL1 蛋白并募集 the E3 ligase Von Hippel-Lindau (VHL)，从而导致泛素化并随后降解致癌融合蛋白。 |
||
| S6794New |
Thalidomide-O-COOH (Cereblon ligand 3)Thalidomide-O-COOH (Cereblon ligand 3) 是基于Thalidomide的 Cereblon (CRBN) 配体，可用于募集CRBN蛋白。Thalidomide-O-COOH (Cereblon ligand 3) 可以通过连接器与蛋白质的配体连接以形成 PROTACs (Proteolysis Targeting Chimera)。 |
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1029 |
Lenalidomide (CC-5013)Lenalidomide (CC-5013)是一种TNF-α分泌抑制剂，在PBMCs中IC50为13 nM。Lenalidomide (CC-5013) 是 ubiquitin E3 ligase cereblon (CRBN) 的配体，它通过CRBN-CRL4泛素连接酶引起两个淋巴样转录因子IKZF1和IKZF3的选择性泛素化和降解。Lenalidomide 可促进 cleaved caspase-3 的表达、抑制 VEGF 的表达并诱导凋亡。 |
Effect of lenalidomide treatment (50 mg/kg/day, p.o. for 3 days) on expression of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), Fas, Fas ligand (FasL), and cleaved caspase-3 in myocardium from lean and ob/ob mice. (a) Representative gel blots of TNF-α, IL-6, Fas, FasL, cleaved caspase-3 and α-Tubulin (as loading control) using specific antibodies. (b) TNF-α. |
|
| S1567 |
PomalidomidePomalidomide (CC-4047)抑制LPS诱导的TNF-α释放，在PBMCs中IC50为13 nM。Pomalidomide 可以在PROTAC中用作靶向 E3 ligase 和抑制 E3 ligase protein cereblon (CRBN)。Pomalidomide可促进凋亡和细胞周期阻滞。 |
OPM2 cells stably expressing either NT or CRBN shRNA were seeded and incubated with pomalidomide at the indicated concentration, followed by MTT assay at day 3 after adding drugs. Each experimental condition was performed in triplicate and repeated at least once.
|
|
| S1193 |
Thalidomide沙利度胺作为一种镇静药，免疫调节剂，也用于研究治疗许多癌症的症状。沙利度胺抑制E3泛素连接酶（一种CRBN-DDB1-Cul4A复合物）。 |
(E) MM.1S cells were treated with Thal(Thalidomide) or Pom for 48 hours. In each case, western blot was carried out using cell lysates and the indicated Abs.
|
|
| S8449New |
VH298VH298 是一种有效的 VHL (Von Hippel-Lindau, the E3 ligase) 的抑制剂，可稳定 HIF-α。VH298 可阻断VHL:HIF-α的相互作用，在等温滴定热分析 (ITC) 中的Kd值为90 nM、在竞争性荧光偏振测定中的Kd值为80 nM。VH-298可用于PROTAC技术。 |
||
| S9605New |
ApcinApcin (APC inhibitor) 是一种有丝分裂的 anaphase-promoting complex/cyclosome (APC/C) 的E3连接酶活性的抑制剂，其可与Cdc20结合并竞争性地抑制含D-box底物的泛素化。 |
||
| S0095New |
VL285VL285 是一种有效的 VHL ligand 对应的IC50值为0.34 μM，可降解HaloTag7融合蛋白。HaloPROTAC3 衍生自 VL285。 |
||
| S0097New |
(S,R,S)-AHPC (MDK7526)(S,R,S)-AHPC (MDK7526) 是一种 VH032-based VHL ligand，可用于募集 von Hippel-Lindau (VHL)蛋白。(S,R,S)-AHPC 可能对 androgen receptor 的靶向降解有用。(S,R,S)-AHPC 可以通过接头与蛋白质的配体例如BCR-ABL1连接，以形成PROTAC例如GMB-475。GMB-475 可在 Ba/F3 细胞中诱导BCR-ABL1降解，IC50值为1.11 μM。 |
||
| S2225 |
TAMETAME是一种APC抑制剂。 |
Knockdown of p21 or inhibiting APC/C by TAME sensitized NSCLC cells to 5-FU. Cells were treated with 5-FU. 2 days after treatment, surviving cells were stained with cystal violet. Representive microscopic fields were shown. The blue stained cells were counted and shown in histogram at the right side.
|
|
| S2781 |
RITA (NSC 652287)RITA (NSC 652287)诱导DNA-蛋白质和DNA-DNA交联，检测不到DNA单链断裂，通过靶向作用于p53，也抑制MDM2-p53相互作用。 |
To determine the number of viable cells, cells were serum starved for 8 hours and treated with 25 nM RITA and stimulated with 1ug/mL SDF1α for 48 hours in serum-free media. After 48 hours, cells were harvested and counted by trypan blue exclusion, using standard methods.
|
|
| S2754 |
AT406 (SM-406)AT406 (SM-406, ARRY-334543, Debio1143) 是一种有效的，拟Smac的IAP(通过E3泛素连接酶起作用的凋亡蛋白抑制剂)拮抗剂，与XIAP-BIR3， cIAP1-BIR3和cIAP2-BIR3结合，Ki为66.4 nM， 1.9 nM和5.1 nM，比作用于Smac AVPI肽亲和力高50到100倍。Phase 1。 |
G, cells treated with the SM406 (1 μmol/L) for 48 hours were subjected to Western blotting. |
|
| S5315 |
PRT4165PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro. |
||
| S8760 |
Iberdomide(CC220)Iberdomide (CC-220) 是一种新型口服免疫调节化合物，靶向cereblon（cereblon是CRL4CRBN E3泛素连接酶复合体的一部分），IC50为60 nM。Iberdomide (CC-220) 可诱导凋亡并具有抗肿瘤和免疫刺激的活性。 |
||
| S7892 |
Avadomide(CC-122)CC-122，一种新型的多效性修饰剂化合物，在弥漫性大B细胞淋巴瘤（DLBCL）中具有抗肿瘤、免疫调节活性。其分子靶标为cereblon (CRBN)，CRBN是E3泛素化连接酶复合体CRL4CRBN的底物受体。 |
||
| S8652 |
Skp2 inhibitor C1 (SKPin C1)Skp2 inhibitor C1 (SKPin C1)是一种高选择性的Skp2-mediated p27 degradation小分子抑制剂。 |
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S2678 |
NSC 207895NSC 207895 (XI-006) 抑制MDMX，IC50为2.5 μM，促进p53稳定/激活和DNA损伤，也调节MDM2（E3连接酶）。 |
Median overall survival of mice (n = 5 mice in vehicle and PYR-41; n = 4 mice in NSC group) inoculated with IOWA-1T xenografts were increased to 43 ± 0.5 and 39 ± 2 days with PYR-41 (PYR) and NSC-207895 (NSC), respectively, compared with a vehicle-treated control group 33 ± 1 days (*p < 0.05).
|
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S1061 |
Nutlin-3Nutlin-3是一种有效的，选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂，无细胞试验中IC50为90 nM；可稳定p53缺陷细胞中的p73。 |
Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.
|
|
| S1172 |
JNJ-26854165 (Serdemetan)JNJ-26854165 (Serdemetan)是一种HDM2泛素连接酶拮抗剂，作用于p53野生型细胞，诱导早期凋亡，在缺乏功能性p53的细胞中，抑制细胞增殖而延迟细胞凋亡。 |
|
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S8975New |
CC-92480CC-92480 是一种新型蛋白降解剂，是一种 cereblon E3 ligase 调节剂(CELMoD)，并具有抗骨髓瘤活性。 |
| 目录号 | 产品描述 | 文献引用 | 实验数据 |
|---|---|---|---|
| S8888New |
GMB-475GMB-475 是一种靶向蛋白水解的嵌合体(PROTAC)，它以变构方式靶向 BCR-ABL1 蛋白并募集 the E3 ligase Von Hippel-Lindau (VHL)，从而导致泛素化并随后降解致癌融合蛋白。 |
||
| S6794New |
Thalidomide-O-COOH (Cereblon ligand 3)Thalidomide-O-COOH (Cereblon ligand 3) 是基于Thalidomide的 Cereblon (CRBN) 配体，可用于募集CRBN蛋白。Thalidomide-O-COOH (Cereblon ligand 3) 可以通过连接器与蛋白质的配体连接以形成 PROTACs (Proteolysis Targeting Chimera)。 |
沪公网安备 31011502012800号